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In normal individuals, the main route for tyrosine degradation is the hepatic pathway tyrosine-4-
hydroxyphenylpyruvic acid_homogentisic acid-CO2. Quantitatively minor pathways, in large part
extrahepatic, are: tyrosine -_ tyramine--octopamine and tyrosine-_dopa--. catecholamines.
In cirrhosis, the main hepatic pathway is blocked to varying degrees at the first three stages. This appears
to be due to lack of activity of the enzymes tyrosine transaminase, PHPA oxidase, and HGA oxidase, the
first step being rate limiting. Hypertyrosinemia and tyrosine intolerance result.
With the main hepatic pathway partially blocked, an abnormally large amount oftyrosine passes into the
normally minor extrahepatic pathway leading to the false neurotransmitters tyramine and octopamine.
Overproduction of these amines ensues and they accumulate in the body fluid.
The false neurotransmitters can displace catecholamines from their storage sites in the peripheral and
central nervous system, and thereby disrupt adrenergic processes in arterioles, kidneys, and brain. Their
accumulation in cirrhotic patients may play a role in the pathogenesis of hepatic encephalopathy,
hepatorenal syndrome, and hyperdynamic circulation.
HISTORY
The earliest recorded observation of deranged tyrosine metabolism in liverdisease
was Rokitansky[1], who in 1849 noted crystals oftyrosine in the liver ofpatients with
acute hepatic necrosis. Five years later Frerichs [2], described tyrosine crystals in the
urine of patients with acute yellow atrophy. In 1924, the indispensable role of the
liver in amino acid catabolism was documented by Bollman, Mann, and Magath [3]
when they showed that hepatectomy abolished the ability of dogs to synthesize urea.
In 1943, Bernhart and Schneider [4], using a colorimetric technique, demonstrated
fasting hypertyrosinemia in patients with liver disease and described tyrosine
intolerance following an oral challenge of this amino acid.
The automated ion-exchange amino acid analyzer, developed in the 1950s,
stimulated interest in plasma amino acid profiles in various disease states. Usingthis
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improved technique Iber [5], in 1957, measured individual amino acid levels in two
normal subjects and in seven cirrhotics, five of whom had hepatic encephalopathy.
The most characteristic features of the "plasma aminogram" in the cirrhotic group
were elevations of both methionine and tyrosine disproportionate to the rise in total
plasma amino acids. This confirmed the research done two years previously by Wu,
Bollman, and Butt, who used paper chromatography to measure amino acid levels in
patients with hepatic coma [6].Iber also found that the level of plasma amino acids
rose with increasing liver decompensation but that the level of total plasma amino
acids was not consistently elevated in hepatic coma. The diagnostic signficance of
hypertyrosinemia in liver disease was first emphasized by Cachin, Durlach, and Blass
[71, who stated that an elevated concentration of plasma tyrosine was the earliest
plasma derangement of liver disease.
In 1967, utilizing a specific fluorometric method, Levine and Conn [8] further
investigated tyrosine metabolism in patients with cirrhosis or hepAtitis and in normal
controls. Fasting tyrosine levels tended to be slightly increased in patients with
hepatitis and biliary obstruction and markedly increased in patients with cirrhosis.
Following an oral load of tyrosine (50 mg/Kg body weight), patients with cirrhosis
demonstrated larger than normal increments in tyrosine levels and delayed return to
fasting levels when compared to normal controls. In patients with liver disease
(particularly cirrhosis) there was marked impairment in tyrosine synthesis following
an oral load of 100 mg/Kg body weight of phenylalanine.
After 1967, with the exception of scattered reports, no new chapters were added to
the story of abnormal tyrosine metabolism in liver disease, and hepatologists'
attention was diverted toward other aromatic compounds incriminated in producing
the neurologic complications of cirrhosis. The failure of the hepatologists to pursue
the mechanism for the tyrosinemia is surprising, becuase (as is reviewed below),
pediatricians during the period 1930-1950 had been successful in delineating the
enzyme defects responsible for hereditary hypertyrosinemia and related hereditary
metabolic disorders.
A new trail of research on aromatic amino acids in cirrhosis emerged when Fischer
and Baldessarini [9] proposed that false neurotransmitters derived from tyrosine
(tyramine and octopamine) were the mechanism responsible for the altered physiol-
ogy of the central nervous, cardiovascular, and renal systems in hepatic failure. They
theoxized that aromatic amines are continually produced by the action of bacterial
decarboxylases upon dietary phenylalanine and tyrosine. In normal individuals, these
bioactive amines are efficiently cleared from the portal blood by hepatic monoamine
oxidases. However, in cirrhotics with impaired hepatocellular function and porta-
systemic shunting, Fischer proposed that these amines enter the systemic circulation
and "flood" the peripheral and central nervous system. Tyramine and octopamine are
indirect sympathomimetic amines whose actions presumably derive from their ability
to release norepinephrine; their chronic accumulation in cirrhosis could deplete
norepinephrine stores and consequently account for the lowered peripheral arteriolar
resistance, peripheral arteriovenous shunts with a secondary hyperdynamic circula-
tion, and impaired renal cortical perfusion [10] seen in cirrhotic patients. In the
central nervous system, such replacement of normal neurotransmitters could cause
the altered mental state and extrapyramidal features of hepatic disease [11]. In
support of this false neurotransmitter hypothesis, Fischer and coworkers described
significant elevations of plasma and urinary octopamine in cirrhotics with hepatic
encephalopathy, with the degree of octopaminuria correlating with the depth of
encephalopathy. Since this original report, Lam et al., in 1973 [12], and Manghani
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et al., in 1975 [13], also were able to demonstrate marked accumulation of octopa-
mine in plasma and urine of encephalopathic cirrhotics. In 1976, Faraj and cowork-
ers [14-16] evaluated the role of plasma tyramine (the metabolic precursor of
octopamine). The tyramine level in cirrhotic patients with encephalopathy was
significantly higher than in normal subjects or in non-encephalopathic cirrhotics.
Plasma tyramine was directly correlated with plasma tyrosine. Increasing dietary
protein from 40 to 80 grams/day increased fasting tyramine concentration 30 to 70
percent within three days in both encephalopathic and non-encephalopathic cir-
rhotics.
To summarize, a disturbance in tyrosine metabolism in cirrhosis has been
recognized for over a century, and there is recent evidence to suggest that deranged
tyrosine metabolism may cause the cardiovascular and neurological complications of
liver disease. Recent investigation has focused on the false neurotransmitters,
tyramine and octopamine, while study of the metabolism of tyrosine itself has been
interrupted prematurely.
The purpose of this article is twofold: to review the metabolic pathways which link
tyrosine, tyramine, and octopamine in health and disease; and to describe recent
studies by the authors on the metabolism of these compounds in normals and
cirrhotics. Our findings lead to a hypothesis explaining the simultaneous accumula-
tion of tyrosine, tyramine, and octopamine in the plasma of cirrhotic patients.
NORMAL TYROSINE METABOLISM
Tyrosine is present in all proteins and is required throughout life for the continuing
synthesis of these macromolecules. Tyrosine can be synthesized from phenylalanine,
so that a diet furnishing the minimum daily requirement (1 gm/day) of the latter
amino acid can be devoid oftyrosine without ill effect. The presence oftyrosine in the
diet, however, reduces the daily requirement of phenylalanine. In practice, the
American diet contains both amino acids in considerable excess over the minimum
daily requirements, viz. about 3-5 grams oftyrosine and 4-5 grams ofphenylalanine
daily. Efficient small intestinal absorption and renal tubular conservation oftyrosine
preserve the.large tyrosine pool from whichtissue proteins, catecholamines, melanin,
and thyroid hormones are synthesized.
The excess oftyrosine in the diet over that needed for biosynthetic processes causes
no problems in the normal individual, because of the efficiency of the pathways for
tyrosine degradation. There are three major pathway for tyrosine metabolism as
illustrated in Fig. 1:
Pathway 1: The main hepatic oxidative pathway for tyrosine degradation, tyr-
PHPA-HGA-CO2 (tyr, PHPA, and HGA signify tyrosine, 4-hydroxy-
phenylpyruvic acid, and homogentisic acid, respectively).
Pathway 2: The quantitatively minor extrahepatic decarboxylation pathway
leading to the false neurotransmitters tyramine and octopamine.
Pathway 3: The quantitatively minor extrahepatic pathway leading to the cate-
cholamines dopamine and norepinephrine. Normally, > 98 percent of tyrosine is
degraded via the main intrahepatic oxidative pathway.
After tyrosine enters the hepatocyte, the first step is a reversible transamination
reaction that yields PHPA and is catalyzed by tyrosine aminotransferase, an enzyme
concentrated in the cytosol and mitochondria ofmammalian liver and having arapid
turnover rate of 3-4 hours. The co-substrate for the aminotransferase is a -
ketoglutarate; pyridoxal phosphate is required for optimal activity. The transamina-
tion reaction is normally rate-limiting for tyrosine oxidase, and although it is
reversible, the equilibrium favors keto-acid formation [17].
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FIG. 1. Pathways of tyrosine metabolism "PH" denotes phenylalanine hydroxylase', "TH", tyrosine hydroxylase;
1DD," dopa decarboxylase; "TT," tyrosine transaminase; "PO," 4-hydroxyphenylpyruvic acid oxidase; "HO," homo-
gentisic acid oxidase; "DBH," dopaminep-hydroxylase; and "MAO," monoamine oxidase.
The second intrahepatic reaction, oxidation of PHPA to HGA, is catalyzed by a
copper-containing enzyme, PHPA oxidase. HGA is formed by a complex series of
reactions involving hydroxylation of the aromatic ring of PHPA, migration of the
pyruvyl side-chain, and decarboxylation to an acetyl side chain.
The final step in the catabolic pathway, oxidation of HGA to 4-maleylacetoacetic
acid, is catalyzed by HGA oxidase, an Fe (II) enzyme found principally in the liver
and requiring reduced glutathione. Both of the aforementioned dioxygenases require
ascorbic acid for maximal activity in vivo. Fumarylacetoacetate is then formed by
isomerization of the maleyl-analog, following which hydrolysis yields fumaric and
acetoacetic acids. The latter product receives a coenzyme A moiety to produce
acetoacetyl-CoA, the process being catalyzed by 3-ketoacid CoA transferase. Ace-
toacetyl CoA is oxidized to acetyl-CoA, which enters the Krebs tricarboxylic acid
cycle to produce high energy phosphates and carbon dioxide.
Pathway 2 for tyrosine metabolism is responsible for the extrahepatic production
oftyramine and octopamine. Normally about 1-2 percent oftotal tyrosine metabolic
flux proceeds through this route. The production oftyramine from tyrosineinvolves
a decarboxylation reaction by aromatic-L-amino acid decarboxylase which is present
in liver, kidney, intestine, brain, adrenal, and lung. David et al. [18,19] have shown
that endogenous production oftyramine from tyrosine via decarboxylation becomes
a major pathway for the catabolism oftyrosine whenthe dietary intake ofthis amino
acid in mice is increased to three times the minimal daily requirement.
The tyramine formed is then oxidized to 4-hydroxyphenylacetic acid by monoa-
mine oxidase (MAO), primarily in the liver. MAO requires NAD as cofactor and
exhibits some substrate inhibition. While MAO is most highly concentrated in the
liver, it is also present in lesser amounts in brain, intestine, kidney, and platelet. A
minor by-product of tyramine metabolism is octopamine, formation of which is
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catalyzed by the action of dopamine p-hydroxylase. It is normally found in
adrenergic nerve terminals at about 5 percent of the normal synaptic vesicle
concentration of norepinephrine. Subsequent degradation of octopamine to 4-
hydroxymandelic acid by MAO occurs principally in the liver, but also to a minor
degree in the brain and heart. Urinary 4-hydroxymandelate is octopamine's major
catabolic metabolite. Tyramine normally may also be excreted by the kidneys [20];
healthy adults excrete approximately 0.5 to 1 mg per day.
Pathway 3 for tyrosine metabolism leads to the catecholamines, and begins with
the formation of dopa from tyrosine by the action of tyrosine hydroxylase which is
present in the adrenal gland, brain, heart, and spleen. The hydroxylase requires
tetrahydropterin and possibly Fe (III) as cofactors, exhibits substrate inhibition
control, and is throught to be the rate-limiting step in catecholamine synthesis. L-
dopa is then decarboxylated to dopamine bythe enzyme dopa decarboxylase, located
in kidney, liver, intestine, brain, tnd lung, and requiring pyridoxal phosphate as a
cofactor. . -hydroxylation of dopamine by the enzyme dopamine-,6-hydroxylase
leads to the formation of norepinephrine, the major neurotransmitter in the peri-
pheral adrenergic nervous system and an important central nervous system (CNS)
neurotransmitter. This enzymatic reaction occurs in the adrenal gland, heart,
sympathetic ganglia, and salivary gland. From norepinephrine, epinephrine is
synthesized principally in the adrenal medulla, heart, and brain by phen-
ylethanolamine-N-methyltransferase. Catecholamines are metabolized in the liver
and in the effector cells by two enzymes catechol-O-methyl transferase and monoa-
mine oxidase, with production of acetylated and 0-methylated products (3-0-
methyldopamine, normetanephrine, metanephrine, homovallinic acid and vanil-
lylmethylacetic acid).
Tyramine and other aromatic amines can also be formed in the gastrointestinal
tract by the action of bacterial decarboxylases on tyrosine and other aromatic amino
acids. Normally the aromatic amines generated within the colon are cleared from the
portal circulation efficiently by hepatic MAO: therefore, systemic bioavailability of
these enteric amines is normally negligible. Decarboxylation of amino acids in the
intestinal wall is an additional source of aromatic amines [21,22]. Such foods as
cheese and red wine have high tyramine concentrations and could contribute
substantially to the metabolic burden of these amines, particularly when MAO is
inhibited by drugs or disease [23].
INBORN ERRORS OF PHENYLALANINE-TYROSINE METABOLISM
During 1932-1953, investigators were successful in identifying several hereditary
blocks in the phenylalanine-tyrosine pathways. Their strategy was similar for each
hereditary syndrome: (1) Identify the metabolites which had accumulated in plasma
and urine; these must have been produced proximal to the block. (2) Perform
oral "loading tests" of each metabolic intermediate in the pathway under study.
(3) Confirm the conclusion about the defective enzyme developed from (1) and
(2) by assaying appropriate enzymes in tissue samples.
Using the above techniques, Grace Medes [24] in 1932, investigated a 49-year-old
man with "hereditary tyrosinosis" who was excreting gram quantities of PHPA. Her
demonstration, that the metabolic defect in this patient was a deficiency of PHPA
oxidase, served as a model for the study of other inborn errors oftyrosine metabo-
lism.
Phenylketonuria is a syndrome characterized by mental retardation, deficient
pigmentation, eczema, seizures, and other neurological symptoms. During 1938-
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1960, Jervis [25] showed the cause to be a deficiency of phenylalanine hydox-
ylase, with consequent accumulation ofphenylalanine, phenylpyruvic acid, and other
phenylalanine metabolites.
Alkaptonuria was among the first hereditary metabolic diseases to be recognized.
This disorder is characterized by degenerative arthritis in middle age, dark urine, and
bluish discoloration of the cartilaginous portion of the ear and of the sclera.
Homogentisic acid accumulates and is deposited in polymerized form as a dark
pigment in connective tissue (ochronosis). HGA is excreted inthe urine in amounts as
great as 1 g/day: oxidation of the urinary HGA leads to the formation of a black
polymer, especially at an alkaline pH. LaDu[26] showed that the disease is caused by
a deficiency of HGA oxidase.
The first description of hereditary tyrosinemia was by Baber in 1956 [27]. The
syndrome comprises renal tubular abnormalities, vomiting, diarrhea, abdominal
enlargement, dyspnea, hemorrhages, edema, ascites, rickets, hepatosplenomegaly,
and occasional mental retardation. The cause is a deficiency of PHPA oxidase.
Biochemical consequences of this deficiency are hypertyrosinemia and abnormally
high urinary excretion of PHPA and its reduction product p-hydroxyphenylacetic
acid.
Thus, inherited disorders of phenylalanine and tyrosine metabolism represent a
spectrum of diseases ranging from minimal clinical symptoms and signs as seen in
alkaptonuria, to life-threatening disorders such as phenylketonuria and hereditary
tyrosinemia. Each disease is characterized by accumulation in plasma and urine of
phenylalanine, tyrosine, or metabolic intermediates in the pathways for degradation
of these amino acids.
ACQUIRED DISORDERS OF TYROSINE METABOLISM IN CIRRHOSIS:
RECENT STUDIES IN THIS LABORATORY
The success ofthe earlier pediatric investigators inidentifying the hereditary blocks
of tyrosine metabolism by means of analyses for metabolic intermediates and by
appropriate loading tests, suggested to us that these same techniques could also be
used to identify the acquired blocks in cirrhosis. We have therefore used these
methods to investigate the main hepatic oxidative pathway (1, in Fig. 1). To
investigate pathway 2, we applied a different technique of metabolic research, which
was borrowed from the clinical pharmacologists. Using the "pharamacokinetic
method" [28,29,30], we studied the mechanism for the accumulation of tyramine by
injecting a tracer dose of the labeled amine and measuring the rate of its turnover in
normal subjects and cirrhotics [31].
The results can be summarized as follows.
(a) Pathway 1: Eighteen cirrhotic patients were studied [32], 13 alcohol-induced
and five post-necrotic. All had liver biopsies and full clinical and biochemical
evaluation; nine were grade A, five grade B, and four grade C by Child's classifica-
tion. All exhibited fasting tyrosinemia and abnormally marked and prolonged
elevation of plasma tyrosine levels after an oral dose of 3 grams of tyrosine
("impaired tyrosine tolerance"). Two intermediates in the pathway, PHPA and
HGA, were measured inthe urine in the basal state, afterthe oral load oftyrosine and
after an oral load of 3 grams of PHPA or HGA. Inthe basal state, and afterthe load
of tyrosine, the urinary excretions of PHPA and HGA were normal. After an oral
load of PHPA or HGA, however, the cirrhotics excreted abnormally large amounts
of PHPA or of HGA, respectively. The severity of the intolerances of tyrosine, of
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PHPA, and of HGA were not correlated with the rate of portal blood flow and
degree of portal shunting, which were evaluated by visceral angiography (venous
phase of superior mesenteric artery angiogram). The lack of correlation between the
metabolic and vascular abnormalities suggested that the metabolic blocks in pathway
1 were mainly caused by enzyme deficiencies rather than by subnormal portal blood
flow.
These findings led to the conclusion that cirrhosis causes loss ofactivity oftyrosine
aminotransferase, PHPA oxidase, and HGA oxidase, the first three enzymes in
pathway 1, but that the rate-limiting enzyme is the aminotransferase. This formula-
tion explains the intolerances of tyrosine, PHPA, and HGA, and the normal urinary
excretion of the latter two intermediates in the basal state and after the tyrosine load.
(b) Pathway 2: Earlier work here [14] and elsewhere [10] had demonstrated that
cirrhosis is accompanied by appreciable accumulations oftyramine and octopamine,
decarboxylated products of tyrosine. These accumulations could result either from
overproduction of tyrosine, consequent to the obstruction in pathway 1 demon-
strated above, or from retardeddegradation, consequent to loss ofhepatic MAO [33]
and lowered hepatic blood flow.
To distinguish between these two possible mechanisms, we evaluated the produc-
tion rate and metabolic clearance rate oftyramine as well as other kinetic parameters
following the single intravenous administration of 3H-tyramine to a group of
cirrhotics and control subjects. The data showed that the plasma clearance of
tyramine in hypertyraminemic cirrhotics was normal (ave. 12 ± 1.88 L/min), but the
rate ofproduction oftyramine was 2 to 10 x elevated (ave. 33.g/minutes). Thus, the
hypertyraminemia was caused by overproduction from tyrosine, not by loss of
capacity to degrade the amine by MAO. As expected from this formulation, the
degree of hypertyraminemia, the magnitude of overproduction of tyramine, and the
severity ofthetyrosineintolerance, were all correlated with each other in thecirrhotic
group studied.
HYPOTHESIS
The data are all consistent with the following scheme. Cirrhotic patients are
blocked at three enzymatic steps in pathway 1: tyrosine aminotransferase, PHPA
oxidase, and HGA oxidase. The rate-limiting obstruction is at the aminotransferase
reaction. As tyrosine accumulates because of this block (hypertyrosinemia), it flows
at an abnormally high rate into pathway 2, with consequent overproduction of
tyramine and octopamine and accumulation of these amines in plasma, tissues, and
urine.
CLINICAL IMPLICATIONS
Fischer and coworkers have suggested [34] that the accumulation of tyramine and
octopamine may contribute to the pathogenesis of 3 common complications of
cirrhosis: hepatic encephalopathy, hyperdynamic circulation, and hepatorenal syn-
drome. These noncatecholic phenylethylamines are believed to utilize the same
uptake system as norepinephrine in entering the adrenergic terminals, and therefore
cause a considerable depletion of tissue norepinephrine when accumulated in
significant quantities. As a result of this disruption of both peripheral and central
adrenergic mechanisms, vasodilatation may occur and this may contribute to the
development of low peripheral resistance, high cardiac output, and renal failure in
cirrhotics. Furthermore, displacement of dopamine and norepinephrine in the CNS
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by tyramine and octopamine could affect brainfunction and consequently lead to the
occurrence of hepatic encephalopathy. These amines cross the blood-brain barrier
only slowly; but tyrosine enters the CNS by a specific transport system, and the
enzymes of pathway 2, present in brain, are capable of producing tyramine and
octopamine locally.
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